1 citations
,
August 2018 in “Journal of The American Academy of Dermatology” Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.
January 2018 in “Surgical and Cosmetic Dermatology” This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.
March 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
February 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This review discusses a study on the efficacy and safety of different doses of dutasteride compared to placebo and finasteride in treating men with androgenetic alopecia and reports no new results.
April 2013 in “The FASEB Journal” In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.
7 citations
,
April 2008 in “Progrès en Urologie”